Benzinga | Sep 30, 2021 04:33PM EDT

Bicycle Therapeutics To Present BT5528 Interim Phase I Data At AACR-NCI-EORTC Virtual International Conference On Molecular Targets And Cancer Therapeutics

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle(r)) technology, today announced that interim Phase I results from its Phase I/II trial of BT5528, a second-generation Bicycle(r) Toxin Conjugate (BTC(tm)) targeting EphA2, has been selected for a plenary oral presentation at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, being held October 7-10, 2021. The Company will host a conference call to discuss the results and provide an update on preliminary findings from the BT8009 program on Thursday, October 7, 2021 at 3:00 p.m. ET.

AACR-NCI-EORTC Plenary Oral Presentation Details:

Title: A first in class phase I/II Study of the Novel Bicyclic Peptide and MMAE Conjugate, BT5528, in patients with Advanced Malignancies Associated with EphA2 Expression

Presenter: Meredith McKean, M.D., Sarah Cannon Research Institute at Tennessee Oncology

Session Title: Tumor-targeted Conjugates: A Growing Family

Date/Time: Thursday, October 7 at 12:50 p.m. ET

Conference Call Details

Bicycle Therapeutics will host a conference call and webcast on Thursday, October 7 at 3:00 p.m. ET to review the data being presented and provide an update on preliminary findings from the BT8009 program. To access the call, please dial (800) 377-9118 (domestic) or (409) 937-8920 (international) and provide the Conference ID 2287246. A live webcast of the presentation will be available on the Investors & Media section of the Bicycle website, bicycletherapeutics.com.